SCHEMBL718278

SCHEMBL718278

COc1ccc2oc(C(Nc3ccc(C(=O)O)cc3)C3CCCCC3)c(C#N)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 1/20 0.38
RCE1 Q9Y256 1/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36
TEAD4 Q15561 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720121 0.88 GCG (0.42) NPC1RAB9APOLBALDH1A1MEN1
SCHEMBL720117 0.87 KMT2A (0.38) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL720543 0.87 NPC1 (0.52) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL721051 0.86 NPC1 (0.45) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL718588 0.84 MEN1 (0.43) NPC1RAB9APOLBALDH1A1MEN1
SCHEMBL716783 0.83 KMT2A (0.39) NPC1RAB9APOLBALDH1A1KMT2A
SCHEMBL717861 0.81 NPC1 (0.39) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL719390 0.79 NPC1 (0.45) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL718372 0.79 RCE1 (0.39) NPC1RAB9AALDH1A1RCE1TEAD4
SCHEMBL3397384 0.77 NPC1 (0.42) NPC1RAB9APOLBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885MAPT 4533/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885MAPT 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.